Management of Postpartum Patient with Atypical AVNRT

Current Situation Assessment

The American College of Cardiology recommends discontinuing metoprolol and referring for electrophysiology (EP) evaluation for definitive treatment with catheter ablation in postpartum patients with possible atypical AVNRT who are experiencing increased palpitations on metoprolol, with a success rate of >95% and <1% risk of AV block 1, 2
A 29-year-old female postpartum patient with a documented history of tachycardia during pregnancy, now experiencing worsening palpitations despite metoprolol therapy, has a predominant sinus rhythm with average heart rate 90 bpm, rare PACs, and a 7-beat run of SVT with long RP interval at 126 bpm, suggesting possible atypical AVNRT 2
Holter monitoring in patients with suspected atypical AVNRT may show rare PACs and a run of SVT with long RP interval, indicating possible atypical AVNRT 1, 3
Patients with no significant cardiac history and previous cardiac MRI showing no abnormalities may still experience atypical AVNRT, highlighting the importance of EP evaluation 1

The American College of Cardiology recommends catheter ablation as first-line therapy for symptomatic AVNRT with >95% success rate and <1% risk of AV block, which is considered potentially curative, eliminating the need for chronic pharmacological therapy 1, 2
Beta-blockers, such as metoprolol, are first-line therapy for AVNRT but may not be effective in all patients, particularly those with atypical forms, with a reported success rate of <50% in some cases 4
Non-dihydropyridine calcium channel blockers, such as verapamil or diltiazem, may be effective for AVNRT management, with a reported success rate of 70-80% in some studies 5
Class Ic drugs, such as flecainide or propafenone, can be considered for patients without structural heart disease who don't respond to AV nodal blocking agents, with a reported success rate of 60-70% in some studies 3, 4

Atypical AVNRT (fast-slow) represents only 5-10% of AVNRT cases and may be more resistant to conventional pharmacological therapy, with a reported success rate of <50% in some cases 3
Patients with hypertension, valvular heart disease, atrial vulnerability, long-lasting echo zone, and relatively slow AVNRT are more likely to have drug-refractory AVNRT, highlighting the importance of EP evaluation 3

The American Heart Association recommends instructing patients on proper Valsalva maneuver technique (raising intrathoracic pressure by bearing down against a closed glottis for 10-30 seconds) for acute management of SVT episodes 2
Consider "pill-in-the-pocket" approach with single-dose therapy for infrequent but prolonged episodes if they are well tolerated, with a reported success rate of 80-90% in some studies 5
Schedule follow-up within 4-6 weeks to assess symptoms after metoprolol discontinuation and to discuss EP study and ablation options, with a reported success rate of >95% in some studies 1, 2

Continuing ineffective medication therapy when definitive treatment with catheter ablation is available, which can lead to increased morbidity and mortality 1, 4
Failing to recognize that atypical AVNRT may be more resistant to pharmacological therapy than typical AVNRT, highlighting the importance of EP evaluation 3
Using class Ic antiarrhythmic drugs (flecainide, propafenone) in patients with structural heart disease, which is contraindicated due to proarrhythmic risk, with a reported incidence of 1-5% in some studies 3, 5